Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVT’s Ranexa Approved For Second-Line Angina

This article was originally published in The Pink Sheet Daily

Executive Summary

The partial fatty oxidation inhibitor will launch in late March.

You may also be interested in...



CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY

CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

A2A-adenosine agonist could see FDA action by mid-March 2008.

CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

A2A-adenosine agonist could see FDA action by mid-March 2008.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel